CEI 382 & 50 Fib Levels Are ImportantCEI has been one of the penny stocks we've written about on the site for weeks now. Since it was at just 35 cents, the stock has been on fire. Of course, taking out the social media hype factor, there are potential technical levels to consider right now. First, the 50 fib line has been an initial level of traffic over the last few months. Whenever CEI has gotten to this point, it has either failed to break or briefly break above and hold as interim support. However, as you can see the last time it jumped above this level, it was fleeting. This time around, there's a lot more daily volume at above-average levels to take into account. What's more, you can see that 382 has consistently remained an upper level of support/resistance, more times acting as resistance (as it did Friday), than support. But again, given the above-average volume, that is something that is very different this time around.
Then you've got strength in energy stocks, in general. That paired with these technical levels could be something to watch heading into the new week and end of the third quarter. You've also got Finviz showing short interest above 24% as of Friday.
Predictions
SENS Continues Holding LevelsPulled SENS back up again after a few weeks and see that it's still holding the same fib and trendline levels as it was when we first drew out the fib retracement. It's also now holding the 50DMA consistently as it steadily rises. For some context, this company develops and commercializes continuous glucose monitoring systems for diabetes patients. Senseonics offers the Eversense and Eversense XL products in its lineup. These are implantable CGM systems for measuring glucose levels with an under-skin sensor, and a removable and rechargeable smart transmitter. Sensonics also offers an app for real-time diabetes metrics monitoring.
Other Highlights:
- HC Wainwright $6 target and buy rating last month
- Collab with University Hospitals Accountable Care Organization
- Raised $50 million in gross proceeds through completion of At-the-Market equity offering program last quarter. Proceeds earmarked "primarily for debt service"
-Year-To-Date up over 320% so far
BTC - GLOBAL SYMMETRY - MARKET MAKERS We have a unique way to predict moves and make big profits !
As you can see on the chart our 3 indicator predicts moves that are happening after and big hedge funds follow :)
Connect with us for more !
US30 THE END ?Wall Street dipped on Wednesday on concerns that the spread of the Delta coronavirus variant could slow economic growth and on uncertainty over the timeline for the Federal Reserve to pull back its accommodative policies.
Shares of tech heavyweights were among losers with Microsoft Corp (NASDAQ:MSFT), Facebook Inc (NASDAQ:FB) and Google-owner Alphabet (NASDAQ:GOOGL) Inc were down between 0.1% and 0.6%.
Nine out of eleven sub-sectors fell with economy-sensitive sectors like industrials, materials and real estate leading declines.
Gains in energy shares helped limit some losses with Exxon Mobil (NYSE:XOM), Chevron (NYSE:CVX), Occidental Petroleum (NYSE:OXY) and Halliburton (NYSE:HAL) up between 0.6% and 0.3%, as oil prices jumped on lower output.
U.S. stocks have come under pressure in recent days as investors have turned increasingly cautious following Friday's weak August payrolls data and uncertainty over the Fed's tapering.
"The big question is the uncertainty around the level of economic growth slowdown, tapering and the potential of escalating inflation," said Sam Stovall, chief investment strategist at CFRA.
"Investors are thinking they don't want to be highly exposed towards potential growth sectors, instead the interest remains towards the safety of tech stocks."
St. Louis Federal Reserve Bank President James Bullard told the Financial Times that the U.S. Federal Reserve should move forward with a plan to trim its massive pandemic stimulus program despite a slowdown in job growth.
Stovall said CFRA economists are lowering the growth forecasts for the third quarter, but were still optimistic for the wider economy to grow for the rest of the year.
The S&P 500 and the Nasdaq have gained around 20% so far this year on support from easy central bank policies, but a jump in coronavirus infections and weak economic data have raised worries on the pace of economic recovery.
At 10:17 a.m. ET, the Dow Jones Industrial Average was down 11.74 points, or 0.03%, at 35,088.26, the S&P 500 was down 2.96 points, or 0.07%, at 4,517.07, and the Nasdaq Composite was down 43.66 points, or 0.28%, at 15,330.67.
Perrigo Company (NYSE:PRGO) Plc jumped 6.1% after the drugmaker said it plans to buy HRA Pharma from investment firms Astorg and Goldman Sachs (NYSE:GS) Asset Management in a deal valued at 1.8 billion euros ($2.13 billion).
Cryptocurrency exchange Coinbase (NASDAQ:COIN) Global Inc fell 3.5% after the U.S. securities regulator threatened to sue the firm if it goes ahead with plans to launch a crypto lending scheme.
Declining issues outnumbered advancers for a 1.29-to-1 ratio on the NYSE and for a 2.13-to-1 ratio on the Nasdaq.
The S&P index recorded 13 new 52-week highs and one new low, while the Nasdaq recorded 31 new highs and 16 new lows.
Good day,𝐂𝐑𝐘𝐏𝐓𝟎-𝐇𝐀𝐂𝐊𝟑𝐑𝐒❕I hope these screenshots will suit your taste of profit😋🔆📈📈
The photos you see below⬇️are the New Predictions📈 at your service 📊👮🏼♀️As always - Risk Management of 1%😉 Let’s wish for the best!
To calculate Your Risk use this formula :
Your Risk / (Your Stop-Loss % / 100)
Example :
50$ / (5% / 100 ) = 50 / 0,05 = 1000 $ (Your position size)
Will It VRPX Right By This Resistance Or Fail Again?VRPX is another one of the former penny stock darlings of the year. Big breakout mid August put it on everyone's radars now it's about sustaining this higher price level and subsequent valuation. At today's price of around $20.25, the market cap is 3.5x the size it was just a few weeks ago. Thanks to FDA related headlines, VRPX stock skyrocketed. "The FDA has indicated that Virpax may pursue an NDA drug approval with the Office of Non-Prescription Drugs. The Company has engaged Syneos Health to assist with the optimal clinical trial design based on an efficient timeline."
Now that it seems to have found a home north of $15, levels are coming to light. Right now it looks like the 50 fib line is that pivot. Following the big breakout it was somewhat of a "no man's land support" and now it has acted as resistance, rejecting VRPX each time it's been tested. However, the last few days have seen an uptick in daily volumes so that could be something to keep a closer eye on right now.
"Regarding the latter, VRPX stock is the latest penny stock darling to experience an explosive move. Monday afternoon, shares were trading below $4.50 & as of mid-morning on Tuesday, the former penny stock broke above $10 a share. Now, if you’re wondering what the VRPX stock forecast is moving forward, your guess is as good as mine. In parabolic instances like this, fundamentals can begin playing a role to justify a stock’s price being so highly valued... VPRX isn’t the only trending penny stock today. Retail traders are posting images of Robinhood charts that include other big movers..."
Read More Link: 4 Trending Penny Stocks On Robinhood You Should Watch Right Now
KALA Levels + Short InfoShort squeeze stocks have become a favorite recently. KALA has started getting wrapped into the conversation. Looking at details from sites like FinViz, short float is around 20% meanwhile the float itself shows to be around 42 million shares. Plotting some levels, you'll notice that KALA is still in the lower channel on the fib retracement slowly heading toward the 786 area. However, before that happens, keep watch on an interim level around $3.40. It was previously a support level in July but seems to have become a resistance level as KALA was strongly rejected right at $3.40 on Friday. Aside from the technical/speculative trend, there are also a few things to watch with the company after a rough first half:
" Kala specializes in eye treatments. Its EYSUVIS is quickly playing a leading role for the company. According to the company, this past quarter, it was a preferred prescription for short-term treatment of dry eye disease. Furthermore, Kala explained that its expanding market access with Commercial and Medicare Part D health plans...Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals, explained, “We are encouraged by the very positive feedback we consistently receive from physicians and patients, who describe EYSUVIS as an effective and comfortable medicine and look forward to building on this foundation as we continue with the EYSUVIS launch. In parallel, we continue to promote INVELTYS and are advancing our pipeline of new chemical entities for front and back of the eye diseases, as we work to build a robust and sustainable portfolio of innovative treatments.” "
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
CLVS back on the low lowCLVS is now back at its November 2020 low. The interesting part of this trend is that it also managed to test, hold, and bounce off of an almost identical level (strong support?). As of Friday afternoon shares retested an interim area of higher traffic that was support earlier in August and late July but now appears to have become a resistance level over the last 3 sessions at least. With the "short squeeze stocks" conversation building steam, it could be interesting for CLVS. Finviz shows the short float percentage at 27% right now.
" The biotech sector may also host some of the other heavily shorted stocks. Phase trial data, scientific reports, and the like all play a role in directional momentum. In this case, Clovis has felt some pressure over the last few quarters. Clinical data on its FAP-2286 platform, along with missed earings, haven’t helped the cause. Then you’ve got news of large, multi-million dollar fundraising initiatives adding more pressure as well. Needless to say, it has happened to hopefully advance the company’s pipeline...Clovis specializes in developing cancer treatments. Its lead candidate Rubraca is an oral treatment being developed in multiple types of tumors. These include ovarian and prostate cancers. It’s approved in the US for maintenance treatment in adults with recurrent epithelial, ovarian, fallopian tube, or primary peritoneal cancers...As far as CLVS being considered one of the “short squeeze stocks,” outlets show that the penny stock’s short-interest sits around 27%. Of course, it isn’t as high as some of the others on this list. However, anything over 20%, by most accounts, can be considered high. "
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
ATER Trying To Redeem ItselfWe've looked at countless charts and share structures of the so called "short squeeze stocks" with ATER popping up. While it isn't the highest short interest, sites like finviz point out a short float percentage of over 20%. Further, the penny stock fell hard in August after filing a registration statement for selling shareholders at 2.7 million shares. Thanks to the likes of SPRT BBIG and even MMAT , these high-short interest stocks are the talk of the market right now. The big question is will they hold up to the hype and how long will the moves last IF they even begin in the first place?
" While no news was announced sparking this gain, we did see many tech penny stocks climb during today’s session. However, it did report its second quarter 2021 financial results only a few weeks ago. In the results, the company reported 14% growth in its revenue YoY to $68.2 million. In addition, it managed to grow its gross margin from 46.7% to 48% in addition to decreasing its operating expenses from $29.4 million to $28.4 million...“This has been a challenging quarter for e-commerce marked by a global supply chain crisis, inflation and an extreme shift in consumer behavior due to the opening of brick and mortar stores after the relaxation of COVID-19 related restrictions...Despite the difficult environment and significant increase in product variable cost, our sales grew on average 20% on a proforma basis across all fourteen brands compared to the second quarter of 2019.” The Co-Founder and CEO of Aterian Inc., Yaniv Sarig "
Quote Source & Read More: These 3 Penny Stocks Exploded on Friday, Here’s Why
Will These Levels MMAT er This Week?MMAT has been on the list of short squeeze stocks recently. SPRT 's big move along with BBIG 's big pop helped spotlight some stocks with higher short interest. For this retracement, we didn't do much more than extend out the same fib retracement we plotted in July, which still appears to show relevancy. What's more, is MMAT has a few other things to keep in mind outside of the typical technical/speculative trends:
" The company recorded 197% revenue growth in the second quarter as it continues seeking new contracts. This comes as Meta Materials works to button up yet another acquisition. This one is for Nanotech Security Corp., valued at just under C$91 million. The deal is expected to expand and speed up Meta’s commercialization strategy. In particular, it brings Nanotech’s electron beam lithography equipment anticipated to decrease production costs noticeably. “Nanotech also adds complementary skillsets which can support META’s markets, accelerating our commercialization plans in verticals such as solar energy, 5G and other antennas, battery and fuel cells, and carbon capture,” said George Palikaras, META’s President and CEO...As it relates to MMAT stock short interest, outlets are showing a short float as of today’s date above 40%. However, it does make sense that some have taken bearish bets on the company considering all of the cash laid out for its current and pending acquisitions. Needless to say, it has been one of the penny stocks to watch this week. "
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
BBIG Move Monday?Ever since we posted an article on BBIG last Friday, the conversation has evolved. What was seemingly just another "short squeeze stock" ended up going viral and seems to be a huge talk on every social media outlet. But With so much hype, it's important to make sure you tune out the noise and look at the full picture. A fib retracement we plotted a while ago was extended to meet up with the recent candles. What's interesting is that the same 50 fib line that acted as a major resistance in February and June held on by a thread Friday BUT this time BBIG managed to close above it just slightly. You've also got the corporate story outside of the technical/speculative "short squeeze" story:
" Shares of BBIG stock have remained on the radar of retail traders for the last few months. As we previously reported, investors anxiously awaited updates surrounding the acquisition of Lomotif Private Ltd. by Vinco and its subsidiary ZASH Global Media and Entertainment. The Lomotif acquisition’s importance was that it’s a Singapore-based video-sharing social networking platform becoming a rival to TikTok and Kuaishou. Fast-forward a bit, and Vinco is now experiencing surging trading action and gained appeal from the Reddit crowd...Lomotif has achieved a record number of Monthly Active Users (MAUs) with over 30 million MAUs, according to Data Analysis Firm Sensor Tower. Furthermore, Vinco recently launched recording Artist Tory Lanez’s album “When It’s Dark” on the E-NFT.com platform. “When It’s Dark” is the first album to go platinum on the blockchain with over 1,000,000 units sold...As far as BBIG stock as a “short squeeze stock to watch,” let’s look at some numbers. According to some outlets reporting short interest, the short float percentage is north of 50%, according to some outlets like FinViz. Given the state of the market and that BBIG has just over 41 million shares outstanding, it could be an interesting thing to track as traders hunt for stocks with high short interest this week. "
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
Stocktwits chart Verasity has arrived !As you see we want to highlight what the future give for the next bullrun wave.
I took tha Parallel fibonacci as it indicates the future points.
From the FIB point side, it can go to 0.08 dollar as you see i have extended the first bullrun fibonacci line.(rose arrow )
If we take tu U-form line , we get 0.10 dollar and as you see most of the bullrun ends with round numbers. If you tell me why it's because maths not lie, like fibonacci lines.
Anyway, thanks to like this analyse and follow on my page and other social media.
Peace and have a nice weekend.
Nifty Prediction for 26th Aug. will Market jump from 16675? Today was very good session.
For tomorrow Flat opening and gap up opening will be good for trade
1.Flat opening- if it crosses slowly slowly 16635 then 16675 will be first target. If it crosses 16675 then next will be 16700
But if it opens flat and go downward slowly and breaks 16600 one PE will be there till 16575 with Strict Stoploss
2.Gap up Opening if it opens above 16700 then surely CE but Wait till levels to be reached. Gap up opens 16675-80 then PE after breaking 16675 next will be 16635
3.Gap Down opens then moves slowly till yesterdays close then take PE but this will be risky. If it follow downward direction then surely PE
Never do trading without stoploss
Thank you
Do We Have SPRT Higher?SPRT has been on an EPIC run. Started as a penny stock and just keeps squeezing and exploding higher. BUT this area that it was recently rejected at is a pretty historic one and I had to pull out the chart way back to the summer of 2011. If you look at where resistance points have been over the last TEN years, You'll see that this $15 area has certainly put up a fight. In both November of 2012 and December of 2013 SPRT was heavily rejected. On top of that, when I plotted a Fib retracement the 236 lines up almost IDENTICALLY with that dotted orange trend line. Now, are these proper levels? If you look in 2013 when it was rejected, SPRT retraced...where?...to the next fib level lower, then bounced. What's more, if you look at the 50 fib, you'll see that plotted on this chart it also has been an area of higher traffic. The big question now is will there be a sell-off thanks to profit taking? Will crypto hype continue fueling the move? Will SPRT make new highs? All good questions and better left answered after checking these levels and seeing what the crypto market does next.
"For the first quarter of the year, Support.com wasn’t much to write home about. However, that all changed toward the start of Q2. This coincided with the $35 million settlement with Office Depot in late March. However, this isn’t the biggest story of 2021 for SPRT stock. Support.com’s core business model is providing support solutions for home-based employees. But despite what you may think about this being a reopening trade, there’s more than meets the eye...A strong mix of “short-squeeze” speculation along with cryptocurrency-fueled action has helped spark a surge over the last few months. The company and Greenidge Generation Holdings plan to merge. This tie-up would create a company focused on bitcoin mining operations...When the initial details were announced, Greenidge said it expects the deal will make it the first publicly traded bitcoin mining company with a wholly-owned power plant. With the special meeting of shareholders set for September 10th, it’s clear that the market is paying close attention. Needless to say, SPRT stock has experienced a massive move in the stocks market this year."
Quote Source & Read More: 5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far
Short Time predictions for BNBlet me know your idea about the chart for short time future about BinanceCoin.
Short Time predictions for BNB UpdateThis is an update for my previous idea, after touching the resistant line, will start to rise again(I hope)
USD/ZMWAs predicted if price breaks K17.88 we'll continue to see a further sell side liquidity to K15.44 as we can already see a break in market structure as the kwacha strengthens.
Reasonable $VRA EOY predictionAs you can see in the chart the green flag represent the best scenario as far as price for $VRA by the EOY, the orange conservative , and the red is the worse cast scenario.
The best case scenario for $VRA within Andrews' Pitchfork Model is that $VRA would have to get outside (specifically about 34% from) that blue upper channel for it to hit $1.08 by the eoy.
What i believe is most likely to happen by the end of the year is that $VRA gets up into the median of this channel and by the eoy it's $.30-.40.
The worse case scenario (which isn't really a bad) is that it ends up in the lower channel and is around $.10-.15.
I have $VRA hitting a $1 sometime in 2022, but as they always say you never know with crypto anything can happen.
MNKD Fibbin AgainMNKD is back at a frequent level of "traffic" this week. After doing a quick retracement we can see that the 618 area continues to act as a magnate a key pivot area. After bouncing off this last time, MNKD has continued higher on a decent multi-day move. Now, moving forward, a fundamental focus could be on what happens with its next potential commercial product, Tyvaso:
MannKind’s collaboration partner, United Therapeutics (NASDAQ: UTHR), previously submitted an NDA to the FDA for its Tyvaso DPI product. This is a potential treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. In response to the strong Q2 performance, Michael Castagna, Chief Executive Officer of MannKind, said, “I am really proud of how our team has executed so far in 2021 supporting the growth of Afrezza and preparing for the potential commercial launch of Tyvaso DPI.” With this as the backdrop for a recent rally in MNKD stock, it could be a sign to have it as one of the penny stocks to watch heading into the second half of the month.
Quote Source & Read More: Best Penny Stocks To Buy Right Now? 5 To Watch Before September
SESN Haven't Seen You In A WhileTook the chart all the way back out to 2015 to find some relevant levels and did a quick fib retracement. Aside from the 236 level being a key point of resistance, in 2015, the area around $5.20 presented an interesting area of high traffic. SESN managed to break through this briefly but as you'll see, it was fleeting after putting in the top that I used as the upper anchor. Heading into the end of the week, this area could be important to watch.
" SENS stock is another decent gainer of the day, pushing up by around 8% in afternoon trading. For some context, Senseonics is a producer of medical products that monitor metrics for those with diabetes. Its product line includes several CGM (continuous glucose monitoring) systems such as the Eversense and Eversense XL...These devices utilize a sensor inserted under the skin to track a patient’s glucose levels. It can then send this data to a smartphone which puts it ahead of the existing technology by quite a ways. At the beginning of this week, Senseonics announced its second-quarter 2021 financial results. In the report, the company posted revenue of around $3.3 million and managed to raise more than $50 million in proceeds through an at-the-market offering...In the U.S. and around the world, diabetes is a condition that affects millions. Because of this, Senseonics could have a sizable market opportunity moving forward. For these reasons, SENS stock could be worth keeping an eye on ."
Quote Source & Read more: Best Penny Stocks to Buy Now? 4 to Watch to Avoid Stock Market Crash
Serving Technicals Up On A PLTRSo I plotted this fib retracement a while ago using all highs and lows since IPO. I also plotted out a trend line that seems to have been an interesting level between the 618 and 50 fib levels. Today's update included an extension of that trendline (in dotted orange). The interesting part of it all is that this remains a key level on the chart and is almost exactly where PLTR was denied after this epic gap-up. Now that it has reclaimed some ground, eyes are on this current resistance to turn support (for longs) as well as the 50 fib level if or when it establishes a new support "up here". With tech flip-flopping, it will be interesting to see how PLTR reacts after 8/12's session.
"One of the best performing industries over the past few months has been in tech stocks. The landscape has drastically changed thanks to the pandemic. Many companies have shifted their tech strategy to move more things online and to a virtual platform... One of the best performing industries over the past few months has been in tech stocks. The landscape has drastically changed thanks to the pandemic. Many companies have shifted their tech strategy to move more things online and to a virtual platform."
Quote & Learn More: Top Tech Penny Stocks To Watch For August 2021
AGEN digging through the CratesAGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from here? A lot of that might have to do with what's coming.
" pipeline treatments like AGEN1777 have gained interest from some of the industry’s leading names. Bristol Myers Squibb ( BMY ) has a global exclusive license with Agenus providing up to $200 million in cash upfront. The company can also receive up to $1.36 billion if it reaches specific milestones and includes royalties upon any sales. The FDA already cleared an Investigational New Drug Application for a Phase 1 dosing with AGEN1777 alone and combined with an anti-PD-1 in solid tumors. That’s expected to begin this quarter...Balstilimab...is something that could be in focus as well. The FDA accepted a Biologics License Application for priority review. A Prescription Drug User Fee Act (PDUFA) target date was also given. December 16th will be the PDUFA date and could present an important one for the company and Balstilimab. Phase 2 data showed a response rate of 20% in PD-L1 positive tumors, an overall response rate of 15%, and a median duration of response of 15.4 months. Furthermore, Phase 2 trial results of balstilimab combined with zalifrelimab (AGEN1884) will be presented at a Mini Oral Session at the European Society for Medical Oncology Congress next month. So plenty to watch if AGEN stock is on your watch list right now. "
Quote Source & Read more On AGEN: Hot Biotech Stocks That Deserve Your Attention In August 2021
